VolitionRx Discusses Promising Clinical Trials Results for its Novel COVID-19 Triage Test

(12:36)

VolitionRx Discusses $28 Million Licensing Deal with Heska and Focus for 2022

(4:53)

VolitionRx Breaks Down Supply Agreement of Nu.Q® Vet Cancer Tests with IDEXX Laboratories

(11:33)

VolitionRx – Commercializing the Nu.Q Vet Cancer Test: Webinar

(36:37)

Volition’s Nu.Q(TM) Vet Assay Detects Two Common Canine Cancers

(2:26)

VolitionRx Provides Update on Animal Health Blood Test Program, Licensing Deals and Focus for 2021

(10:16)

Executive interview - VolitionRX discusses Q319 results and provides a business update

(7:56)

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

(3:23)

VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

(3:42)

Volition's 2020 Capital Markets Day Video

(1:16:27)

Bioverse Episode 10 - The Winners, Losers, and Dark Horses of ASCO24 \u0026 BIO2024 tidbits

(1:41:35)

You Need To Pay Attention To Volition Stock NYSE: VNRX

(1:48)

Rethinking the approach to diagnose cancer: VolitionRx Limited (NYSE AMERICAN: VNRX) 重塑癌症診斷方法

(15:51)

An interview with Cameron Reynolds providing a Volition Update and introduction of New Team Members.

(10:23)

Management of Polycythemia Vera with Dr. Aaron Gerds

(56:45)

VolitionRx well funded as it advances development of its novel cancer tests

(10:11)

Business Update with Cameron Reynolds

(5:20)

Revolutionizing The Diagnosis of Life-Altering Diseases - VolitionRx Limited. at GCFF Nov 16, 2022

(18:51)

VolitionRX announces 2nd financials as company look to accelerate growth

(6:47)

VolitionRx on Commercial Launch of Cancer Screen Test for Canines and Veterinary Market Opportunity

(10:3)

VolitionRx - executive interview

(9:12)

Cancer Diagnosis by Blood Tests: VolitionRx Limited (NYSE AMERICAN: VNRX) Presents at GCFF Jun10

(19:43)

VolitionRx (VNRX) - Cameron Reynolds President \u0026 CEO

(25:12)

VolitionRx chief: US patent crucial for long-term value

(9:2)

Executive Interview - VolitionRx

(8:11)

VolitionRx Limited Announces Interim Results from a 680-Subject Clinical Trial in Colorectal Cancer

(5:26)

VolitionRx acquires epigenetic reagent company Octamer GmbH

(3:27)

VolitionRx - executive interview

(8:2)